Source:http://linkedlifedata.com/resource/pubmed/id/11228377
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
15-16
|
pubmed:dateCreated |
2001-3-6
|
pubmed:abstractText |
The immunogenicity of three currently used hepatitis B vaccines was compared in an unselected study population in an every day travel clinical setting. Five hundred and eighteen vaccinees received Engerix-B (EB), 990 received Twinrix (TWX), and 366 were immunised with Gen-HB-Vax (GHB). Overall, 88.6% of the vaccinees, tested within the first 6 months after completion of the vaccination series, developed protective levels of anti-HBs (> or = 10 mIU/ml). However, GHB recipients showed significantly lower seroprotection rates (SPR) than EB and TWX recipients (79.3% vs. 87.7% vs. 92.3%, P < 0.000001). GMTs for anti-HBs, tested within 6 months after the third vaccination, showed the lowest results in the GHB group, followed by EB and TWX (142 vs. 523 vs. 1008 mIU/ml, P < 0.000001). TWX vaccinees, however, showing a higher antibody decline rate than EB recipients within the first years after completion of the full immunisation course (30% vs. 25%; P = 0.0538). This study confirms an overall good immune response to the 20 microg-dose vaccine, in the course of a regular clinical setting. The significant difference in SPRs and GMTs to the 10 microg-dose vaccine, however, may influence future immunisation practices for the elderly.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Engerix-B,
http://linkedlifedata.com/resource/pubmed/chemical/Gen-H-B-Vax,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0264-410X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2055-60
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11228377-Adolescent,
pubmed-meshheading:11228377-Adult,
pubmed-meshheading:11228377-Age Factors,
pubmed-meshheading:11228377-Aged,
pubmed-meshheading:11228377-Aged, 80 and over,
pubmed-meshheading:11228377-Ambulatory Care Facilities,
pubmed-meshheading:11228377-Child,
pubmed-meshheading:11228377-Female,
pubmed-meshheading:11228377-Hepatitis B,
pubmed-meshheading:11228377-Hepatitis B Antibodies,
pubmed-meshheading:11228377-Hepatitis B Vaccines,
pubmed-meshheading:11228377-Humans,
pubmed-meshheading:11228377-Male,
pubmed-meshheading:11228377-Middle Aged,
pubmed-meshheading:11228377-Travel,
pubmed-meshheading:11228377-Vaccines, Synthetic
|
pubmed:year |
2001
|
pubmed:articleTitle |
Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience.
|
pubmed:affiliation |
Department of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Kinderspitalgasse 15, A-1095, Vienna, Austria. joy.pamela.wagner@univie.ac.at
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Multicenter Study
|